1. Home
  2. SGHT vs STRO Comparison

SGHT vs STRO Comparison

Compare SGHT & STRO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Sight Sciences Inc.

SGHT

Sight Sciences Inc.

HOLD

Current Price

$5.33

Market Cap

235.0M

Sector

Health Care

ML Signal

HOLD

Logo Sutro Biopharma Inc.

STRO

Sutro Biopharma Inc.

HOLD

Current Price

$38.69

Market Cap

338.9M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
SGHT
STRO
Founded
2011
2003
Country
United States
United States
Employees
N/A
131
Industry
Medical Specialities
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
235.0M
338.9M
IPO Year
2021
N/A

Fundamental Metrics

Financial Performance
Metric
SGHT
STRO
Price
$5.33
$38.69
Analyst Decision
Buy
Buy
Analyst Count
7
9
Target Price
$9.08
$31.33
AVG Volume (30 Days)
325.3K
248.1K
Earning Date
05-06-2026
05-11-2026
Dividend Yield
N/A
N/A
EPS Growth
28.16
N/A
EPS
N/A
N/A
Revenue
$77,363,000.00
N/A
Revenue This Year
$11.67
N/A
Revenue Next Year
$10.39
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$3.11
$0.67
52 Week High
$9.24
$41.88

Technical Indicators

Market Signals
Indicator
SGHT
STRO
Relative Strength Index (RSI) 69.62 66.08
Support Level $3.29 $0.78
Resistance Level $5.66 N/A
Average True Range (ATR) 0.38 3.05
MACD 0.14 0.12
Stochastic Oscillator 80.93 66.21

Price Performance

Historical Comparison
SGHT
STRO

About SGHT Sight Sciences Inc.

Sight Sciences Inc is an ophthalmic medical device company focused on the development and commercialization of surgical and nonsurgical technologies for the treatment of prevalent eye diseases. The company operates through two segments: Interventional Glaucoma, which generates the majority of revenue and includes the OMNI Surgical System family of products and the SION Surgical Instrument used in minimally invasive glaucoma surgery to reduce intraocular pressure in adult patients with open-angle glaucoma; and Interventional Dry Eye, which includes the TearCare System, an interventional device designed to melt and facilitate the removal of meibomian gland obstructions and restore gland functionality in adult patients with evaporative dry eye disease.

About STRO Sutro Biopharma Inc.

Sutro Biopharma Inc is a clinical-stage drug discovery, development, and manufacturing company. It is mainly engaged in the development of biopharmaceutical products. The company manufactures next-generation protein therapeutics for cancer and autoimmune disorders through its proprietary integrated cell-free protein synthesis platform, XpressCF. Products offered by the company include STRO-001 for patients with multiple myeloma and non-Hodgkin lymphoma and STRO-002 for the treatment of ovarian and endometrial cancers. The company also pipeline contains STRO-004, STRO-006, STRO-00X, STRO-00Y, STRO-003, VAX24, VAX31, and Others.

Share on Social Networks: